Details of the Drug
General Information of Drug (ID: DMN19QP)
Drug Name |
4-amino-N-(4-iodophenyl)benzenesulfonamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
6965-75-9; NSC63371; 4-amino-N-(4-iodophenyl)benzenesulfonamide; 4-amino-n-(4-iodo-phenyl)-benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(4-iodophenyl)-; 4-amino-N-(4-iodophenyl)benzene-1-sulfonamide; Benzenesulfonamide,4-amino-N-(4-iodophenyl)-; NSC 63371; Enamine_003086; AC1Q6VVM; AC1Q51XD; AC1L6LA2; AC1Q51XC; 4-IODOSULFANILANILIDE; CHEMBL227416; CTK5D0764; DTXSID00219913; MolPort-001-833-979; HMS1402M06; ZINC537958; NSC-63371; STK063720; AKOS000115972; NE11209; MCULE-7780071880; KB-290010; EN300-02869; SR-01000033730
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 374.2 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||